Equity Profile

EXEL

Exelixis, Inc.

Health CareBiotechnology$14.1B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Exelixis, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for cancer....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth will provide insights into the demand for Exelixis's products and overall business performance.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

EXEL Q2-2026 Earnings Preview

Context

Company Snapshot

Exelixis, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for cancer. With a market cap of $14 billion, it plays a significant role in the health care sector, particularly in oncology treatments.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+57.79%

Avg Stock Reaction

-0.79%

Last Quarter Recap

In Q1-2026, Exelixis reported an EPS of $0.87, exceeding expectations by 29.27%. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Continued focus on advancing clinical trials for new therapies.
Commitment to maintaining strong financial performance.
Plans to enhance market presence through strategic partnerships.

Expectations

Wall Street Expectations

Overall expectations for Exelixis are cautiously optimistic, given their strong track record of beating EPS estimates. However, the lack of revenue guidance leaves some uncertainty.

Bull Case

If Exelixis continues its trend of exceeding EPS expectations and provides positive updates on drug approvals, investor confidence could rise significantly.

Bear Case

On the other hand, if the company fails to meet EPS expectations or lacks clarity on future revenue growth, it could lead to a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated EPS for Q2-2026?

Given the company's strong history of beating EPS estimates, this number will be critical for investor sentiment.

What are the latest developments regarding drug approvals?

Updates on drug approvals can significantly influence future revenue and market confidence in Exelixis.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Exelixis's potential for strong EPS growth based on its recent performance and ongoing clinical trials.

Supporting Evidence

The company has consistently beaten EPS estimates, suggesting strong operational efficiency.

Options pricing reflects a low expected move, indicating that traders may not fully appreciate the potential upside.

The lack of revenue guidance could mean that positive surprises are more likely than anticipated.

Key Risk

If EPS comes in below $0.70, it could significantly undermine the bullish consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Exelixis can maintain its strong earnings performance amidst competitive pressures and regulatory challenges.

Bull Confirmed If

An EPS of $0.90 or higher would confirm the bull case, indicating strong profitability.

Bear Confirmed If

An EPS below $0.70 would support the bear case, raising concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±1.04%

Historical Avg

±1.1%

In line with history

The options market is pricing in a modest move, suggesting that traders expect limited volatility around the earnings announcement.

Options are pricing ±1.0% while EXEL has averaged ±1.1% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.4%

30d HV

44.8%

Calls (200K)P/C Ratio: 3.58Puts (2K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Exelixis beats expectations, history suggests the stock could rise by about 1.14%, confirming strong investor confidence.

In-Line / Cautious

If results are in line but lack guidance, expect muted market reaction, as investors may remain cautious.

Miss

If the company misses EPS expectations, history suggests a potential decline of around 0.79%, which could shake investor confidence.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on drug approval timelines and their potential impact on revenue.
2Details on cost management strategies and their effect on profitability.
3Insights into market competition and how Exelixis plans to maintain its edge.
4Any commentary on partnerships or collaborations that could enhance growth.
5Management's outlook on the overall oncology market and Exelixis's positioning within it.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Exelixis, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for cancer....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth will provide insights into the demand for Exelixis's products and overall business performance.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

EXEL Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+57.79%

Avg Stock Reaction

-0.79%

Last Quarter Recap

In Q1-2026, Exelixis reported an EPS of $0.87, exceeding expectations by 29.27%. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Continued focus on advancing clinical trials for new therapies.
Commitment to maintaining strong financial performance.
Plans to enhance market presence through strategic partnerships.

Expectations

Wall Street Expectations

Overall expectations for Exelixis are cautiously optimistic, given their strong track record of beating EPS estimates. However, the lack of revenue guidance leaves some uncertainty.

Bull Case

If Exelixis continues its trend of exceeding EPS expectations and provides positive updates on drug approvals, investor confidence could rise significantly.

Bear Case

On the other hand, if the company fails to meet EPS expectations or lacks clarity on future revenue growth, it could lead to a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated EPS for Q2-2026?

Given the company's strong history of beating EPS estimates, this number will be critical for investor sentiment.

What are the latest developments regarding drug approvals?

Updates on drug approvals can significantly influence future revenue and market confidence in Exelixis.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Exelixis's potential for strong EPS growth based on its recent performance and ongoing clinical trials.

Supporting Evidence

The company has consistently beaten EPS estimates, suggesting strong operational efficiency.

Options pricing reflects a low expected move, indicating that traders may not fully appreciate the potential upside.

The lack of revenue guidance could mean that positive surprises are more likely than anticipated.

Key Risk

If EPS comes in below $0.70, it could significantly undermine the bullish consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Exelixis can maintain its strong earnings performance amidst competitive pressures and regulatory challenges.

Bull Confirmed If

An EPS of $0.90 or higher would confirm the bull case, indicating strong profitability.

Bear Confirmed If

An EPS below $0.70 would support the bear case, raising concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±1.04%

Historical Avg

±1.1%

In line with history

The options market is pricing in a modest move, suggesting that traders expect limited volatility around the earnings announcement.

Options are pricing ±1.0% while EXEL has averaged ±1.1% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.4%

30d HV

44.8%

Calls (200K)P/C Ratio: 3.58Puts (2K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Exelixis beats expectations, history suggests the stock could rise by about 1.14%, confirming strong investor confidence.

In-Line / Cautious

If results are in line but lack guidance, expect muted market reaction, as investors may remain cautious.

Miss

If the company misses EPS expectations, history suggests a potential decline of around 0.79%, which could shake investor confidence.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on drug approval timelines and their potential impact on revenue.
2Details on cost management strategies and their effect on profitability.
3Insights into market competition and how Exelixis plans to maintain its edge.
4Any commentary on partnerships or collaborations that could enhance growth.
5Management's outlook on the overall oncology market and Exelixis's positioning within it.